Assessment of Adding Fenofibrate to Simvastatin on Exercise Test Findings in Patients with Dyslipidemia and Coronary Artery Disease
Message:
Abstract:
Introduction
Cardiac events due to coronary artery disease (CAD) are the most common cause of death in all over the world. Myocardial ischemia and its consequent heart failure are considered as common problems and complications of CAD. The purpose of this study was to assess the anti-ischemic effects of fibrates in patients with CAD.
Methods
This clinical-trial study was conducted on patients with dyslipidemia and CAD referred to the Baqiyatallah university hospital، Tehran، during 2008-2010. A total of 124 patients randomly divided into two groups: the first group (64 patients) received simvastatin (20-60 mg/day) +fenofibrate (200 mg/day) with lipid-limited diet and exercise and the second group (60 patients) received simvastatin (20-60 mg/day) with diet and exercise for one year and the patients were evaluated at the end of this period.
Results
The mean age was 54. 3±6. 5 years and 53. 2% of patients were male. Metabolic equation index was changed from 4. 32±0. 5 to 5. 68±0. 5 at the first group (P<0. 001) and 4. 43±0. 9 to 4. 41±1. 1 at the other one (P=0. 121) and also time of exercise was changed from 5. 21±1. 81 to 6. 01±1. 8 (P<0. 001) and 5. 43±1. 26±5. 23±1. 2 (P=0. 089) respectively. No serious adverse effects were seen.
Conclusion
Lipid-lowering therapy with simvastatin and fenofibrate reduces myocardial ischemia. Therefore it’s recommended to add fenofibrate to statinsin the treatment ofdyslipidemia in patients with high risk of cardiovascular accidents as complementary treatment.
Language:
Persian
Published:
Journal of Ardabil University of Medical Sciences, Volume:13 Issue: 50, 2013
Pages:
406 to 412
magiran.com/p1210054  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 990,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
دسترسی سراسری کاربران دانشگاه پیام نور!
اعضای هیئت علمی و دانشجویان دانشگاه پیام نور در سراسر کشور، در صورت ثبت نام با ایمیل دانشگاهی، تا پایان فروردین ماه 1403 به مقالات سایت دسترسی خواهند داشت!
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 50 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!